Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Status:
Completed
Trial end date:
2018-11-28
Target enrollment:
Participant gender:
Summary
To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in
children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who
are in remission.